AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8164614 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 24
Study 8164614 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 3296295 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (breathing exercises emphasizing inspiration with forced expiration technique in gravity assisted positions)
Number of subjects: 18
Study 3296295 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (breathing exercises with positive expiratory pressure alternating with forced expiration technique in gravity assisted positions)
Number of subjects: 18
Study 3296295 — intervention group
Group type: COMPARATOR
Intervention: Treatment C (breathing exercises with positive expiratory pressure and forced expiration technique in sitting position)
Number of subjects: 18
Study 30311825 — intervention group
Group type: EXPERIMENTAL
Intervention: α-Lipoic Acid (7 mg/kg), Carnosine (6 mg/kg), Thiamine (1 mg/kg)
Number of subjects: 82
Study 30311825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 27561937 — intervention group
Group type: EXPERIMENTAL
Intervention: VBAC (TOLAC)
Number of subjects: 507
Study 27561937 — intervention group
Group type: EXPERIMENTAL
Intervention: VBAC
Number of subjects: 507
Study 27561937 — intervention group
Group type: COMPARATOR
Intervention: ERCS
Number of subjects: 507
Study 25123219 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day-week therapy
Number of subjects: 283
Study 25123219 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit class therapy
Number of subjects: 283
Study 25123219 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 283
Study 23249479 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based course on management of atopic dermatitis with email/MMS guidance; Duration: 6 months
Number of subjects: 46
Study 23249479 — intervention group
Group type: COMPARATOR
Intervention: No education or guidance (control group)
Number of subjects: 46
Study 19934443 — intervention group
Group type: EXPERIMENTAL
Intervention: EXDASE program (3-month duration)
Number of subjects: 52
Study 18522057 — intervention group
Group type: EXPERIMENTAL
Intervention: R package for single-case randomization tests
Number of subjects: 0
Study 15516351 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% plus 0.150 mg of clonidine
Number of subjects: 80
Study 15516351 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.5% plus 1 ml of NaCl 0.9% (Control)
Number of subjects: 80
Study 15516351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plus 0.150 mg of clonidine
Number of subjects: 80
Study 15516351 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% plus 1 ml of NaCl 0.9% (Control)
Number of subjects: 80
Study 12806381 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate (6-monthly injections)
Number of subjects: 50
Study 12806381 — intervention group
Group type: COMPARATOR
Intervention: Goserelin acetate (6-monthly injections)
Number of subjects: 50
Study 10368835 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal lateral pinch grip efforts in individuals with myotonic dystrophy
Number of subjects: 18
Study 8677864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory electrocardiographic (AECG) monitoring
Number of subjects: 1820
Study 2053506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (15 mg daily) - simplified three-step regimen
Number of subjects: 173
Study 2053506 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (15 mg daily) - standard seven-step regimen
Number of subjects: 173
Study 2053506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (15 mg daily) - both regimens
Number of subjects: 173
Study 6336981 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus T (cyclophosphamide, methotrexate, 5-fluorouracil plus tamoxifen)
Number of subjects: 145
Study 6336981 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 145
Study 6336981 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus T
Number of subjects: 145
Study 6336981 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 145
Study 6336981 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line CMF plus T
Number of subjects: 145
Study 6336981 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (CMF)
Number of subjects: 145
Study 6336981 — intervention group
Group type: COMPARATOR
Intervention: Treatment B (CMF plus T)
Number of subjects: 145
Study 30958066 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg/BM)
Number of subjects: 15
Study 29956572 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits by pharmacists (academic detailing)
Number of subjects: 307
Study 26993976 — intervention group
Group type: EXPERIMENTAL
Intervention: WATCHMAN device
Number of subjects: 485
Study 25005467 — intervention group
Group type: EXPERIMENTAL
Intervention: IV abatacept (10 mg/kg) plus methotrexate (MTX)
Number of subjects: 219
Study 21816029 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine with booster dose of RTS,S/AS01
Number of subjects: 6000
Study 21816029 — intervention group
Group type: COMPARATOR
Intervention: RTS,S/AS01 vaccine with control vaccine at time of booster
Number of subjects: 6000
Study 21816029 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine at time of primary vaccination and booster
Number of subjects: 6000
Study 21816029 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 6000
Study 19947263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medicine group
Number of subjects: 92
Study 19947263 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group
Number of subjects: 92
Study 17713976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50mg orally
Number of subjects: 11
Study 17713976 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin 25mg intravenous infusion
Number of subjects: 11
Study 15733479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine infusion (20 microg.kg(‐1).h(‐1))
Number of subjects: 30
Study 15733479 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia (1 MAC)
Number of subjects: 30
Study 15733479 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine infusion
Number of subjects: 30
Study 15733479 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 30
Study 11999816 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (CA)
Number of subjects: 68
Study 11999816 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine plus aspirin (TA)
Number of subjects: 68
Study 9550505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution (HHD) with 10% hydroxyethyl starch 200/0.5 (HES) over 5 days
Number of subjects: 200
Study 9550505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pure rehydration with Ringer's lactate)
Number of subjects: 200
Study 9550505 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution (HHD)
Number of subjects: 200
Study 9550505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 7886396 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (50 mM, pH 5.7)
Number of subjects: 11
Study 7886396 — intervention group
Group type: EXPERIMENTAL
Intervention: D-tryptophan (50 mM, pH 5.7)
Number of subjects: 11
Study 7886396 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan and D-tryptophan (50 mM, pH 5.7)
Number of subjects: 11
Study 7886396 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (pH 5.5)
Number of subjects: 11
Study 2896402 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg acetylsalicylic acid
Number of subjects: 2500
Study 2896402 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg acetylsalicylic acid
Number of subjects: 2500
Study 2896402 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 2500
Study 2896402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 29464680 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 79
Study 29464680 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral Incision of the Prostate (TUIP)
Number of subjects: 79
Study 29464680 — intervention group
Group type: COMPARATOR
Intervention: Control (TURP vs TUIP)
Number of subjects: 79
Study 27058906 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 supplementation (4,000 IU [100 μg] daily)
Number of subjects: 229
Study 27058906 — intervention group
Group type: COMPARATOR
Intervention: Matching non-calcium-based placebo
Number of subjects: 229
Study 25027749 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 3 gr every 6 hours for 72 hours
Number of subjects: 44
Study 25027749 — intervention group
Group type: COMPARATOR
Intervention: Control group received all standard ICU therapies
Number of subjects: 44
Study 23022759 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH-nadroparin calcium (0.3 or 0.4 mL sc) administered 2 hours before surgery
Number of subjects: 100
Study 23022759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium administered daily post-surgery
Number of subjects: 100
Study 23022759 — intervention group
Group type: COMPARATOR
Intervention: Control group received LMWH-nadroparin calcium 8 hours after surgery
Number of subjects: 100
Study 20223782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Bayes model for surgical procedure choice
Number of subjects: 0
Study 18614928 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbicide active against curable STIs
Number of subjects: 0
Study 16095253 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by research assistants from the local community
Number of subjects: 0
Study 16095253 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12585970 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose regimen of cotrimoxazole
Number of subjects: 18
Study 12585970 — intervention group
Group type: COMPARATOR
Intervention: Escalating dose regimen of cotrimoxazole starting with 75 mg/day, doubled every 48 hours
Number of subjects: 18
Study 10717551 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional movement analysis system
Number of subjects: 81
Study 9053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysucrose 15000 (PS 15000)
Number of subjects: 20
Study 9053970 — intervention group
Group type: EXPERIMENTAL
Intervention: 51Cr-labelled ethylenediaminetetraacetic acid (EDTA)
Number of subjects: 20
Study 9053970 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-mannitol
Number of subjects: 20
Study 9053970 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal
Number of subjects: 20
Study 2149912 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms Ethinylestradiol (EE) and 150 micrograms Desogestrel (DG)
Number of subjects: 34
Study 2149912 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms Gestodene (GD)
Number of subjects: 34
Study 7018361 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride/Hydrochlorothiazide (A/HCTH) combination
Number of subjects: 43
Study 7018361 — intervention group
Group type: COMPARATOR
Intervention: Furosemide plus potassium supplementation (FUR/P)
Number of subjects: 43
Study 31603582 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (Battlefield protocol)
Number of subjects: 134
Study 31603582 — intervention group
Group type: COMPARATOR
Intervention: Control (bandages alone)
Number of subjects: 134
Study 31603582 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 134
Study 30392736 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid test group
Number of subjects: 254
Study 30392736 — intervention group
Group type: COMPARATOR
Intervention: Control standard-of-care group
Number of subjects: 254
Study 28089680 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS2 participants with AMD
Number of subjects: 484
Study 28089680 — intervention group
Group type: COMPARATOR
Intervention: Control subjects without AMD
Number of subjects: 484
Study 25575067 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC)
Number of subjects: 100
Study 25575067 — intervention group
Group type: COMPARATOR
Intervention: leflunomide (LEF)
Number of subjects: 100
Study 24041733 — intervention group
Group type: EXPERIMENTAL
Intervention: Four sessions of birth and parent preparation in small groups
Number of subjects: 2350
Study 24041733 — intervention group
Group type: COMPARATOR
Intervention: Two lectures in an auditorium
Number of subjects: 2350
Study 22028163 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy for four weeks
Number of subjects: 18
Study 22028163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 18
Study 18953549 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm (sodium hyaluronate-based bioresorbable membrane)
Number of subjects: 427
Study 18953549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Seprafilm)
Number of subjects: 427
Study 18953549 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm
Number of subjects: 427
Study 18953549 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 427
Study 16215804 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12183857 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 10480500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 14
Study 10480500 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 14
Study 8763180 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcation advancement closure
Number of subjects: 25
Study 8763180 — intervention group
Group type: COMPARATOR
Intervention: Patch angioplasty
Number of subjects: 25
Study 8763180 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 25
Study 8763180 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifurcation advancement
Number of subjects: 25
Study 8763180 — intervention group
Group type: COMPARATOR
Intervention: Patch closure
Number of subjects: 25
Study 2009893 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 12
Study 2009893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7064673 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Bandi procedure (anterior displacement of the tibial tuberosity)
Number of subjects: 42
Study 7064673 — intervention group
Group type: COMPARATOR
Intervention: Standard shaving procedure
Number of subjects: 42
Study 31488156 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 157
Study 31488156 — intervention group
Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 157
Study 28327693 — intervention group
Group type: EXPERIMENTAL
Intervention: Single visit treatment
Number of subjects: 199
Study 28327693 — intervention group
Group type: COMPARATOR
Intervention: Two visits with 1-week intracanal calcium hydroxide medication
Number of subjects: 199
Study 26499256 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT model (intervention group)
Number of subjects: 1200
Study 26499256 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1200
Study 23708174 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 8782
Study 23708174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8782
Study 23708174 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg and Placebo
Number of subjects: 8782
Study 21513721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic i.c.v. application of ghrelin in rats
Number of subjects: 0
Study 21513721 — intervention group
Group type: EXPERIMENTAL
Intervention: Single s.c. injection of ghrelin under cold exposure in mice
Number of subjects: 0
Study 21513721 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-hour intravenous ghrelin infusion in healthy humans
Number of subjects: 0
Study 19948089 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 17429911 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% glucose
Number of subjects: 110
Study 17429911 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 110
Study 16491678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (10,000 lux)
Number of subjects: 31
Study 16491678 — intervention group
Group type: COMPARATOR
Intervention: Red dim light placebo condition (200 lux)
Number of subjects: 31
Study 12021712 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous obliteration
Number of subjects: 28
Study 12021712 — intervention group
Group type: COMPARATOR
Intervention: Conventional stripping operation
Number of subjects: 28
Study 10619348 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg po QID for 6 weeks
Number of subjects: 6
Study 7553992 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidifier group (n = 10) using humidified and warmed gases at 40 degrees C
Number of subjects: 30
Study 7553992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal group (n = 10) using an oesophageal heat exchanger
Number of subjects: 30
Study 7553992 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10) with no active warming
Number of subjects: 30
Study 1933205 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In‐labelled P256 Fab' imaging
Number of subjects: 17
Study 1933205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐arterial thrombolysis
Number of subjects: 17
Study 1933205 — intervention group
Group type: COMPARATOR
Intervention: Negative scans
Number of subjects: 17
Study 1933205 — intervention group
Group type: COMPARATOR
Intervention: Arteriographic appearances
Number of subjects: 17
Study 6804164 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD (30 micrograms/day)
Number of subjects: 110
Study 6804164 — intervention group
Group type: COMPARATOR
Intervention: Copper-releasing IUD (Nova-T)
Number of subjects: 110
Study 29558784 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (25 mg/daily)
Number of subjects: 80
Study 29558784 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide extended‐release (30 mg/daily for HbA1c 7.5‐8.0% and 60 mg/daily for HbA1c 8.0‐8.5%)
Number of subjects: 80
Study 30091945 — intervention group
Group type: COMPARATOR
Intervention: VAC (Vincristine, Dactinomycin, and Cyclophosphamide)
Number of subjects: 448
Study 30091945 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC/VI (Vincristine and Irinotecan)
Number of subjects: 448
Study 27555196 — intervention group
Group type: EXPERIMENTAL
Intervention: Active prewarming with a Mistral‐Air warming system initially set to 43°C
Number of subjects: 115
Study 27555196 — intervention group
Group type: COMPARATOR
Intervention: No active prewarming
Number of subjects: 115
Study 24169460 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at adiposity rebound (AR)
Number of subjects: 2880
Study 24169460 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak weight velocity (PWV)
Number of subjects: 2880
Study 24169460 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI at age at adiposity rebound (AR)
Number of subjects: 2880
Study 24169460 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak height velocity (PHV)
Number of subjects: 2880
Study 22882750 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC)
Number of subjects: 0
Study 22882750 — intervention group
Group type: COMPARATOR
Intervention: Standard-exposure tacrolimus (TAC Control)
Number of subjects: 0
Study 20972845 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavocoxid (500 mg twice daily)
Number of subjects: 220
Study 20972845 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 220
Study 17687150 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (n=6 RCTs)
Number of subjects: 1500000
Study 17687150 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (n=3 cohort studies)
Number of subjects: 1500000
Study 17687150 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (n=9 case-control studies)
Number of subjects: 1500000
Study 15875108 — intervention group
Group type: EXPERIMENTAL
Intervention: High right atrial pacing (HRA)
Number of subjects: 79
Study 15875108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual site right atrial pacing (DAP)
Number of subjects: 79
Study 15875108 — intervention group
Group type: COMPARATOR
Intervention: Standard pacing (SP)
Number of subjects: 79
Study 11952485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide TID for 6 weeks
Number of subjects: 47
Study 11952485 — intervention group
Group type: COMPARATOR
Intervention: Placebo TID for 6 weeks
Number of subjects: 47
Study 9796227 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed-mood induction
Number of subjects: 0
Study 9796227 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema induction organized around the theme of writing a paper
Number of subjects: 0
Study 9796227 — intervention group
Group type: COMPARATOR
Intervention: Arousal induction
Number of subjects: 0
Study 9796227 — intervention group
Group type: COMPARATOR
Intervention: Control neutral-mood induction
Number of subjects: 0
Study 8684925 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Variability
Number of subjects: 48
Study 8684925 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked Variability
Number of subjects: 48
Study 8684925 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific
Number of subjects: 48
Study 8684925 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 8684925 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study 1710741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg t.i.d.)
Number of subjects: 0
Study 1710741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0